Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 34 for:    PROACT
Previous Study | Return to List | Next Study

PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? (PROACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03265574
Recruitment Status : Recruiting
First Posted : August 29, 2017
Last Update Posted : October 24, 2022
Sponsor:
Collaborators:
Newcastle University
University of Durham
Newcastle-upon-Tyne Hospitals NHS Trust
Information provided by (Responsible Party):
South Tees Hospitals NHS Foundation Trust

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant epirubicin-based chemotherapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Non Hodgkin Lymphoma Drug: Enalapril Phase 3

Detailed Description:

PROACT is a phase 3 randomised, open label, blinded endpoint, superiority trial of enalapril to prevent anthracycline-induced in patients treated for breast cancer and lymphoma.

Anthracyclines used in the treatment of breast cancer cause damage to heart muscle cells; this results in cell death (cardiotoxicity). In UK contemporary practice, epirubicin is the most frequently used anthracycline.

Patients due to receive adjuvant anthracycline chemotherapy (planned epirubicin dose >300mg/m2) for breast cancer at four specialist centres in the North of England will be invited to participate. 170 eligible patients will be randomised in a 1:1 ratio, to either enalapril plus usual care or to usual care. Enalapril will be commenced prior to the first anthracycline dose, titrated to a maximum tolerated dose, and continued during chemotherapy. Chemotherapy will continue per usual care; typically six treatment cycles. Patients will have a blood test performed at the end of each chemotherapy cycle to measure cardiac troponin, and at one month following the last epirubicin dose. Investigators and patients will be blinded to the troponin results. Patients will have an echocardiogram at baseline and following their chemotherapy; they will be assessed in a blinded manner by a central Core Laboratory.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity
Actual Study Start Date : October 4, 2017
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : May 31, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention Drug: Enalapril
Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
No Intervention: Standard care


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cardiac troponin T release [ Time Frame: One month after last dose of anthracycline ]
    Cardiac troponin T release during anthracycline treatment


Secondary Outcome Measures :
  1. Cardiac function [ Time Frame: One month after last dose of anthracycline ]
    Cardiac function assessed by echocardiogram

  2. Adherence to enalapril [ Time Frame: One month after last dose of anthracycline ]
    Ability of participant to adhere to enalapril

  3. Adverse Events / Reactions [ Time Frame: One month after last dose of anthracycline ]
    Number and severity of Adverse Events and Reactions

  4. Anxiety or distress related to trial participation [ Time Frame: One month after last dose of anthracycline ]
    Anxiety or distress related to trial participation

  5. Cancer and chemotherapy outcomes [ Time Frame: One month after last dose of anthracycline ]
    Cancer and chemotherapy outcomes in the population under study

  6. Cardiac troponin I release [ Time Frame: One month after last dose of anthracycline ]
    cardiac troponin I release during anthracyline treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent.
  • Adult patients with histopathologically* confirmed breast carcinoma who have received surgery for their breast cancer; planned to receive 6 cycles of EC 90 (total planned dose 540mg/m2 epirubicin) or FEC 75 (total planned dose 450mg/m2 epirubicin) adjuvant chemotherapy regimen. Patients with HER2+ breast cancer are eligible for inclusion.

OR

  • Adult patients with histopathologically confirmed non-Hodgkin lymphoma (NHL), planned to receive 6 cycles of R-CHOP or CHOP (total planned dose 300mg/m2 doxorubicin) chemotherapy**

    • Patients with HER2+ breast cancer are eligible for inclusion. ** Patients who will receive an alternative anti-CD20 monoclonal antibody are eligible (for example O-CHOP), as long as the total planned doxorubicin dose is ≥300mg/m2 over 6 cycles

Exclusion Criteria:

  • Positive baseline cardiac troponin T (≥14ng/L);
  • known contraindication to ACE inhibitor e.g. renal artery stenosis, severe aortic stenosis;
  • are taking, or have a previous intolerance to ACEI (e.g. angioedema);
  • patient already taking other agents acting on the renin-angiotensin-aldosterone system e.g. Aliskiren, angiotensin receptor blockers (ARBs), Entresto (sacubitril/valsartan), spironolactone, eplerenone;
  • LVEF <50%*;
  • estimated GFR < 30 mL/min/1.73m2 at baseline;
  • hyperkalaemia defined as serum potassium ≥5.5mmol/L;
  • symptomatic hypotension, or Systolic Blood Pressure <100mmHg;
  • poorly-controlled hypertension (Blood Pressure >160/100mmHg**, or ambulatory BP of 150/95mmHg);
  • previous myocardial infarction;
  • known metastatic breast cancer;
  • previous exposure to anthracycline chemotherapy;
  • are pregnant or breastfeeding;
  • previous Herceptin treatment or planned Herceptin treatment within four weeks following anthracycline chemotherapy;
  • for patients of childbearing potential: refusal to use adequate contraception throughout the trial;***
  • any other invasive cancer diagnosed and treated in the past 5 years;
  • symptomatic or severe asymptomatic radiation-induced cardiac disease;
  • judgement by the investigator that the patient has a prognosis of < 1 year or are unlikely to complete 6 cycles of chemotherapy;
  • judgement by the investigator that the patient is high risk for tumour lysis syndrome (applicable only to NHL patients);

  • judgement by the Investigator that the patient should not participate in the study, for example, if the patient is unlikely to comply with study procedures, restrictions, and requirements.

    *<50% as defined by Simpson's biplane method; if absolute measurements are not possible, then a visually normal assessment of LVEF is acceptable for inclusion.

    **White coat hypertension is more common, and should be ruled out by an ambulatory blood pressure monitor

    ***Female patients between the ages of 18 and 50 will receive a pregnancy test at baseline. Adequate methods of contraception are those that can achieve a failure rate of less than

    1% per year when used consistently and correctly, such methods include:

  • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation

    • oral
    • intravaginal
    • transdermal

  • progestogen-only hormonal contraception associated with inhibition of ovulation

    • oral
    • injectable
    • implantable
  • intrauterine device (IUD)
  • intrauterine hormone-releasing system (IUS)
  • bilateral tubal occlusion
  • vasectomy/vasectomised partner
  • true sexual abstinence
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03265574


Contacts
Layout table for location contacts
Contact: David Austin 01642 850850 ext 55909 david.austin@nhs.net
Contact: Victoria Hildreth 0191 208 5825 PROACT@ncl.ac.uk

Locations
Layout table for location information
United Kingdom
South Tees Hospitals NHS FT Recruiting
Middlesbrough, Teesside, United Kingdom, TS4 3BW
Contact: David Austin         
Sponsors and Collaborators
South Tees Hospitals NHS Foundation Trust
Newcastle University
University of Durham
Newcastle-upon-Tyne Hospitals NHS Trust
Investigators
Layout table for investigator information
Study Chair: Victoria Hildreth Study Chair
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: South Tees Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT03265574    
Other Study ID Numbers: 2016152
First Posted: August 29, 2017    Key Record Dates
Last Update Posted: October 24, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Breast Neoplasms
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
 Breast Diseases
Skin Diseases
Enalapril
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents